Generic drugmaker Mylan's 2Q profit jumps 28 pct - WBOY.com: Clarksburg, Morgantown: News, Sports, Weather

Generic drugmaker Mylan's 2Q profit jumps 28 pct

Posted: Updated:
  • BusinessBusinessMore>>

  • Union workers at Frontier OK 3-year contract

    Union workers at Frontier OK 3-year contract

    Monday, September 1 2014 12:17 PM EDT2014-09-01 16:17:18 GMT
    The new contract will expire in August 2017. It covers about 1,500 employees in 42 West Virginia counties.
    The new contract will expire in August 2017. It covers about 1,500 employees in 42 West Virginia counties.
  • Shale activity spurs WesBanco growth

    Shale activity spurs WesBanco growth

    Monday, September 1 2014 10:00 AM EDT2014-09-01 14:00:29 GMT
    Managing growth has been a problem for some companies in the shale gas region of West Virginia, leading WesBanco to provide services to help them.
    Managing growth has been a problem for some companies in the shale gas region of West Virginia, leading WesBanco to provide services to help them.
  • WV workforce lacks oil and gas expertise — for now

    WV workforce lacks oil and gas expertise — for now

    Sunday, August 31 2014 5:00 PM EDT2014-08-31 21:00:19 GMT
    Despite the relatively high amount of natural gas production in West Virginia, less than 3 percent of employees in some of the major occupations that make up the sector's workforce live in the Mountain State.
    Despite the relatively high amount of natural gas production in West Virginia, less than 3 percent of employees in some of the major occupations that make up the sector's workforce live in the Mountain State.

CANONSBURG, Pa. (AP) — Mylan Inc.'s second-quarter earnings jumped 28 percent, as a drop in expenses helped the generic drugmaker counter sluggish revenue growth.

The Canonsburg, Pa., company said Thursday it earned $177.7 million, or 46 cents per share, in the three months that ended June 30. That compares to earnings of $138.6 million, or 33 cents per share, in last year's quarter. Adjusted earnings, which exclude restructuring charges, amortization expense and other items, totaled 68 cents per share.

Revenue rose less than 1 percent to $1.7 billion.

Analysts surveyed by FactSet expected, on average, earnings 67 cents per share on $1.73 billion in revenue.

Mylan said foreign exchange rates hurt its revenue in this year's quarter, and the company received a boost in last year's quarter from the launch of a generic version of the antidepressant Lexapro.

The company's selling, general and administrative expenses fell 12 percent in this year's quarter to $315.4 million.

Mylan also said Thursday it was reaffirming its forecast for 2013 adjusted earnings of between $2.75 and $2.95 per share. It also expects revenue to be at the low end of its expected range of $7 billion to $7.4 billion in part because of the negative effect of foreign currency.

Analysts expect, on average, earnings of $2.87 per share on revenue of $7.06 billion.

For the third quarter, Mylan expects to earn 77 cents to 79 cents per share on an adjusted basis; analysts expect 87 cents per share.

Mylan shares climbed 21 cents to $33.77 in morning trading, while the Nasdaq exchange on which the stock trades rose about 1 percent. The stock has ranged between $22.50 and $34.62 over the past year.

 

Copyright 2013 The Associated Press